Emerging Lipoprotein Markers Slightly Up CVD Risk Detection

This article originally appeared here.
Share this content:
Emerging Lipoprotein Markers Slightly Up CVD Risk Detection
Emerging Lipoprotein Markers Slightly Up CVD Risk Detection

(HealthDay News) – The addition of certain apolipoproteins and lipoproteins to cardiovascular disease (CVD) risk scores containing total cholesterol and high-density lipoprotein cholesterol (HDL-C) slightly improves CVD risk prediction, according to a study published in the June 20 issue of the Journal of the American Medical Association.

Emanuele Di Angelantonio, MD, of the University of Cambridge in the United Kingdom, and colleagues reviewed data from 37 prospective cohorts involving 165,544 participants, all without baseline CVD.

During a median of 10.4 years of follow-up, the researchers found that there were up to 15,126 incident CVD outcomes. The addition of various lipid-related markers to total cholesterol, HDL-C, and conventional risk factors resulted in improved discrimination, with a C-index change of 0.0006 for the combination of apolipoprotein B and A-I; 0.0016 for lipoprotein(a); and 0.0018 for lipoprotein-associated phospholipase A2 mass. The addition of each of these markers to risk scores containing conventional risk factors resulted in net reclassification improvements of less than 1%. For adults aged 40 years or older, using conventional risk factors alone, 15,436 of 100,000 would be initially classified at intermediate risk. Using additional testing, 1.1% would be reclassified with a combination of apolipoprotein B and A-I; 4.1% with lipoprotein(a); and 2.7% with lipoprotein-associated phospholipase A2 mass to a 20% or higher predicted CVD risk category, which would necessitate statin treatment under Adult Treatment Panel III guidelines.

"The clinical benefits of using any of these biomarkers remains to be established," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs